Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

SOLVE-TAVI after 12-month followup: self-expanding vs. balloon expandable and general vs. local anesthesia

The ambitious SOLVE-TAVI (soon to be published in JACC) is aimed at answering to of the most important questions we make when facing a TAVR procedure: What valve do we choose, a self-expanding or a balloon expandable? And once we have chosen our device, do we proceed with general anesthesia or conscious sedation? 

Sedación consciente vs anestesia general en el TAVI

 

The SOLVE-TAVI had already shown no major differences at 30 days between devices or sedation strategies. At present, after one year, we look forward to these results. 

Using a 2 × 2 factorial design, 447 intermediate to high-risk patients with severe, symptomatic aortic stenosis were randomly assigned to transfemoral TAVR using the self-expanding Evolut R vs. the balloon expandable Sapien 3.  Following the 2 x 2 design, patients were randomized to general anesthesia vs. conscious sedation at the same time. 

When comparing devices, the combined end point rate (all-cause mortality, stroke, moderate to severe paravalvular leak and need of permanent pacemaker implantation) resulted similar between prosthesis at one year (38.3% vs 40.4%, HR 0.94, CI 95% 0.7 to 1.26; p=0.66).

As regards sedation, outcomes were as disappointing: general anesthesia resulted similar to conscious sedation when it came to the combined end point of all-cause mortality, stroke, MI and acute kidney injury (25.7% vs 23.8%, HR 1.09, CI 95% 0.76 to 1.57; p=0.63).


Read also: TCT 2018 | SOLVE-TAVI: Self-Expandable vs. Balloon-Expandable Valves and General vs. Local Anesthesia in One Study.


Probablemente, para la enorme mayoría de los pacientes la elección de la válvula o el tipo de anestesia todavía pase por la experiencia de cada operador y equipo. Sin embargo, existen diferencias sutiles de subgrupos que pueden inclinar la balanza hacia una u otra válvula como también al tipo de anestesia.

Conclusión

En pacientes de riesgo intermedio o alto que reciben TAVI transfemoral no se observaron diferencias al año entre las actuales generaciones de la válvula autoexpandible y la válvula balón expandible. Los tipos de anestesia tampoco mostraron diferencias significativas en el mismo período de tiempo.

Título original: Impact of Anesthesia Strategy and Valve Type on Clinical Outcomes After Transcatheter Aortic Valve Replacement.

Referencia: Hans-Josef Feistritzer et al. J Am Coll Cardiol. 2021 May, 77 (17) 2204–2215.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

TAVI in TAVI: Clinical and Hemodynamic Outcomes According to the Type of Prosthesis Used in TAVI-in-TAVI

With the expansion of TAVI to younger and lower surgical risk patients, bioprosthetic valve degeneration and the need for repeat interventions are expected to...

Percutaneous Closure of Patent Foramen Ovale in Patients Over 60 Years Old With Cryptogenic Stroke: A Safe and Effective Strategy?

Cryptogenic stroke accounts for up to one-third of all ischemic strokes and remains strongly associated with the presence of a patent foramen ovale (PFO),...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...